Marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte

La sensibilisation croissante au diabète et aux maladies rénales a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'augmentation du nombre d'appareils de point de service améliorés pour le diabète contribue également à la demande croissante de tests de diabète ou d'HBA1C.

Data Bridge Market Research analyse que le marché des tests HbA1c devrait croître avec un TCAC de 4,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 61,59 millions USD d'ici 2030 en Arabie saoudite et en Turquie. Le marché des tests HbA1c devrait croître avec un TCAC de 5,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 73,73 millions USD d'ici 2030 en Turquie et en Égypte. Le segment des instruments devrait propulser la croissance du marché grâce au développement de technologies avancées   

Définition du marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte

A blood test called a haemoglobin A1C (HbA1C) test reveals your average blood sugar (glucose) level over the previous two to three months. Your blood contains glucose; a form of sugar that is obtained from the food you eat. Glucose provides energy to your cells. The hormone insulin aids in the uptake of glucose by your cells. If you have diabetes, your body either produces insufficient insulin, or your cells don't properly utilize it. Because of the inability of glucose to enter your cells, your blood sugar levels rise.  

Diabetes is a global endemic with rapidly increasing prevalence in developing and developed countries. Glycated hemoglobin (HbA1c) as a possible substitute to fasting blood glucose for diagnosis of diabetes HbA1c is an important indicator of long-term glycemic control with the ability to reflect the cumulative glycemic history of the preceding two to three months. HbA1c provides a reliable measure of chronic hyperglycemia and correlates well with the risk of long-term diabetes complications. Elevated HbA1c has also been regarded as an independent risk factor for coronary heart disease and stroke in subjects with or without diabetes. The valuable information provided by a single HbA1c test has rendered it a reliable biomarker for the diagnosis and prognosis of diabetes. However, the High cost of HBA1C testing devices and kits and standards for the approval and commercialization of products is expected to restrain the market growth.

Saudi Arabia, Turkey, and Egypt HbA1c Testing Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Increasing prevalence of diabetes worldwide

The number of young people under age 20 with diabetes is likely to increase more rapidly in future. There are also various studies for the rise in type 2 diabetes including the increasing prevalence of childhood obesity. The presence of diabetes in people of childbearing age might is much important because maternal diabetes increases risk of diabetes in children.

The rising demand for hba1c testing with improved accuracy and less time constraint are pushing the key players for strategic initiatives. As people with diabetes are at higher risk for heart disease or a stroke, diabetes complications and premature death than those who do not have diabetes

• Growing awareness about the importance of glycemic control

Poor glycemic control is characterized by the chronically high levels of blood sugar and glycated hemoglobin such as diabetic patients especially those treated with insulin are at risk for developing hypoglycemia. Some studies suggest that an increase in non-exercise physical activity is effective in reducing postprandial hyperglycemia and improving glycemic control

Various studies revealed that many diabetic patients had inadequate and poor glycemic control levels. And this was associated with older age, longer duration of DM, insulin therapy, poor diet compliance, and failure to set control goals. This requires focusing on the identified factors and tailored management mechanisms to maintain good glycemic control. So, people are getting more concerned over this factor and preparing themselves to control their level of glycemic

However, a low level of knowledge of diabetes may act as a predictor of poor glycemic control but not as a medication adherence.

Restraint

• High cost OF hba1c testing devices and kits

The devices and kits cost plays important role in the hba1c testing market. As the development process for these devices and kits is quite expensive and take a long time to pass through R&D, regulatory and various other compliances. These devices and kits requires a start with a high-level understanding of the process from a design to production to the way the product will be manufactured as a single error in any stage can cause disruption in the whole production.

For Instance,

• In December 2020, as per NCBI article, in Saudi Arabia the health expenditure for people diagnosed with diabetes compared to expenditure in the absence of diabetes is ten times higher

However, these hba1c devices and kits demand an effective investment for successful operations along with a project risk management plan.

Opportunity

• Increasing adoption of hba1c testing in emerging markets

The regulations and doctor recommendation plays important role in increasing adoption of hba1c testing. The stringent rules and regulations are necessary for government approval to ensure the security and safety of the humans and environment. As hba1c is one of the commonly used test to diagnose prediabetes and diabetes and is also considered the main test to help you and your health care team manage your diabetes. Pre-diabetics or people having borderline diabetes, are also advised by doctors to get tested to check how stable their blood sugar levels are. In general doctor’s opinion people having diabetes and pre-diabetes should get their HbA1c tested every 3 months.

Challenge

• Challenges in interpreting hba1c results in patients with anemia or kidney disease

The underlying challenges associated with the predictive ability of HbA1c persist in chronic kidney disease environments. Excess fluid and waste from blood remain in the body and may cause other health problems such as heart disease and stroke.

However, HbA1c levels may be falsely elevated or decreased in chronic kidney disease because a uremic environment shortens the red blood cell lifespan. Several studies have provided the speculation that in populations with a high prevalence of inflammation and malnutrition, such as chronic kidney disease HbA1c levels could be less predictive of clinical outcomes.

For instance-

• In February 2022 – As per ncbi article study conducted by researchers in the gulf cooperation council countries stated that HbA1c level of 7% to 8% may be the most favorable for the best outcomes for diabetes mellitus patients in advanced chronic kidney disease

However, mild-to-moderate anemia and chronic kidney disease may not affect the relationship between glycated hemoglobin and blood glucose level.

Recent Developments

• In March 2020, PTS Diagnostics recently announced that they would launch A1CNow+ Controls for the A1CNow®+ Test System. A1CNow+ Controls are initially accessible in the US, EU, and UK. They can be kept frozen for up to three years, chilled for eight months, or at room temperature for seven days. The solution has two levels, each in a dropper-style vial, and may be effectively used in minutes. Its goal is to ensure accurate A1C findings.
• In March 2023, Abbott announced a definitive agreement with Cardiovascular Systems, Inc. (CSI), a manufacturer of medical devices with a cutting-edge atherectomy system used to treat peripheral and coronary artery disease, under which Abbott would purchase CSI. Abbott's market-leading vascular device lineup will gain access to fresh, complementary innovations thanks to the purchase of CSI. This has caused the business to grow for the corporation.

Saudi Arabia, Turkey, and Egypt HbA1c Testing Market Scope

Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into five notable segments such as product type, mode of testing, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY PRODUCT TYPE

• Instruments
• Reagents And Consumables

On the basis of product type, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into instruments, reagents, and consumables.

BY MODE OF TESTING

• Prescription Based Testing
• OTC Testing

On the basis of mode of testing, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into prescription based testing and OTC testing.

BY TECHNOLOGY

• Turbidimetric Inhibition Immunoassay
• Ion-Exchange HPLC
• Affinity Binding Chromatography
• Enzymatic Assay
• Others

On the basis of technology, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into ion exchange HPCL, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others.

BY END USER

• Laboratories
• Hospitals
• Clinics
• Homecare
• Ambulatory Centers
• Pharmacies/Drug Stores
• Others

Sur la base de l'utilisateur final, le marché des tests HbA1c d'Arabie saoudite, de Turquie et d'Égypte est segmenté en laboratoires, hôpitaux, cliniques, soins à domicile, centres ambulatoires, pharmacies/pharmacies et autres.

PAR CANAL DE DISTRIBUTION

• Vente directe
• Distribution par des tiers
• Ventes au détail

Sur la base du canal de distribution, le marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte est segmenté en distribution à des tiers, ventes directes et ventes au détail.

Analyse/perspectives régionales du marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte

Le marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte est segmenté en quatre segments notables tels que le type de produit, le mode de test, la technologie, l'utilisateur final et le canal de distribution.

Les pays couverts par ce rapport de marché sont l'Arabie saoudite, la Turquie et l'Égypte. La Turquie devrait dominer le marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte en raison de la prévalence croissante du diabète et du prédiabète au sein de la population.

La section États du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse de la concurrence et des parts de marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte

Le paysage concurrentiel du marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte fournit des détails par concurrent. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'ampleur du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte.

Certains des principaux acteurs opérant sur le marché des tests HbA1c en Arabie saoudite, en Turquie et en Égypte sont Siemens Healthcare GmbH, A. Menarini Diagnostics srl, ARKRAY, Inc., Trinity Biotech, Thermo Fisher Scientific Inc., Abbott, Wondfo, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, DxGen Corp. et entre autres.

SKU-69907